Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
2.590
+0.080 (3.19%)
At close: Apr 2, 2025, 4:00 PM
2.569
-0.021 (-0.81%)
After-hours: Apr 2, 2025, 6:00 PM EDT
Evoke Pharma Revenue
In the year 2024, Evoke Pharma had annual revenue of $10.25M with 97.84% growth. Evoke Pharma had revenue of $3.31M in the quarter ending December 31, 2024, with 97.40% growth.
Revenue (ttm)
$10.25M
Revenue Growth
+97.84%
P/S Ratio
0.47
Revenue / Employee
$3,416,472
Employees
3
Market Cap
5.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.25M | 5.07M | 97.84% |
Dec 31, 2023 | 5.18M | 2.67M | 106.51% |
Dec 31, 2022 | 2.51M | 890.57K | 55.04% |
Dec 31, 2021 | 1.62M | 1.60M | 6,929.00% |
Dec 31, 2020 | 23.02K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
EVOK News
- 19 days ago - Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 27 days ago - Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 - GlobeNewsWire
- 5 weeks ago - Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - GlobeNewsWire
- 3 months ago - Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends - GlobeNewsWire
- 4 months ago - Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® - GlobeNewsWire
- 4 months ago - InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience - Business Wire
- 5 months ago - Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results - GlobeNewsWire